Obesity
Obesity sits at the center of the Cardiovascular-Kidney-Metabolic (CKM) framework reshaping how the industry thinks about risk – and it's where our depth runs deepest.
As GLP-1 and SGLT2, MRA and other new therapies deliver benefits that cut across metabolic, renal, and cardiovascular endpoints at once, understanding how prescribers and payers are actually navigating overlapping conditions and fragmented care across these therapies, before it shows up in share data, is what separates brands that win market position from brands that defend it.
Subscribe for Obesity updates
About Obesity
Obesity has become the center of gravity in metabolic disease. GLP-1 receptor agonists – and the rapidly expanding pipeline behind them – are driving treatment decisions not just for weight, but for the conditions increasingly linked to it, above all MASH and kidney risk.
Clinically and commercially, that convergence is increasingly organized under the Cardiovascular-Kidney-Metabolic (CKM) framework – the American Heart Association’s 2023 designation for the overlapping risk pathways connecting obesity, kidney disease, and cardiovascular outcomes, and now the lens many med affairs, HEOR, and market access teams use to structure strategy. Spherix tracks that convergence starting from where our expertise runs deepest: Obesity. The other two legs of the CKM continuum – CKD-ND and MASH – are covered by our Nephrology and Gastroenterology practices, with direct cross-links from this page.
INDICATIONS COVERED
- Chronic Kidney Disease, Non-Dialysis (CKD-ND)
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Obesity
Cardiometabolic and renal care are being redrawn by a single class of therapies. GLP-1 receptor agonists, first established in diabetes and obesity, are now demonstrating meaningful cardiovascular and kidney protection. SGLT2 inhibitors, with the same origin, have become foundational therapy in chronic kidney disease and heart failure. And MASH, long defined by unmet need, shares underlying metabolic drivers and an overlapping patient population with obesity and diabetic/chronic kidney disease. The result is a set of conditions that used to sit in separate franchises, and separate budgets, now competing for the same prescribers, the same payer policies, and increasingly the same patients.
Spherix has tracked this cardiometabolic/renal overlap for years and has launched dedicated coverage in 2026, working with leading and emerging biopharma companies shaping innovation across obesity, MASH, and kidney disease. The Spherix community of practicing endocrinologists, gastroenterologists, hepatologists, nephrologists, cardiologists, and/or physicians/APPs are continuously screened for active practice and patient volume. Spherix publishes multiple studies annually across physician, patient, and payer perspectives.
The insights that inform confident, strategic decisions
The Spherix three-perspective lens applied to obesity:
physician
How endocrinologists, obesity medicine specialists, primary care physicians, and hepatologists are adopting and sequencing GLP-1 therapies for obesity and MASH – including how those prescribing patterns align with the Cardiovascular-Kidney-Metabolic (CKM) framework many organizations now use to structure medical and commercial strategy.
Patient
Treatment burden, adherence, and persistence for patients on GLP-1 therapy, including the added complexity when MASH or kidney risk is also part of the clinical picture.
payer (market access)
Formulary and coverage dynamics for GLP-1s in obesity and emerging MASH therapies, including how payers are increasingly evaluating these categories through a converged CKM lens rather than siloed indications.
Spherix clients have exclusive access to
Research products
Therapeutic expertise and advisory
Customization and targeting
AI-assisted synthesis
Strategic positioning and messaging
Related Articles
Meet the Team
